Medartis Holding (VTX:MED) results for the first half of 2024

Key financial results

• Sales: CHF 111.5 million (up 8.0% compared to the first half of 2023).

• Net profit: CHF 2.57 million (after a loss of CHF 848,000 in the first half of 2023).

• Profit margin: 2.3% (after the net loss in H1 2023).

• Earnings per share: CHF 0.19 (after CHF 0.07 loss in the first half of 2023).

All figures shown in the graph above refer to the last 12 months (TTM)

Insights into Medartis Holding’s profits

An average sales growth of 14% per annum is expected for the next three years. In comparison, the growth forecast for the medical technology industry in Switzerland is 8.0%.

Performance of Swiss medical device industry.

The company’s shares fell 4.9 percent compared to the previous week.

Risk analysis

Please note that Medartis Holding 3 warning signals in our investment analysis you should know this…

Do you have feedback on this article? Are you concerned about the content? Contact us directly from us. Alternatively, send an email to editorial-team (at) simplywallst.com.

This Simply Wall St article is of a general nature. We comment solely on the basis of historical data and analyst forecasts, using an unbiased methodology. Our articles do not constitute financial advice. It is not a recommendation to buy or sell any stock and does not take into account your objectives or financial situation. Our goal is to provide you with long-term analysis based on fundamental data. Note that our analysis may not take into account the latest price-sensitive company announcements or qualitative materials. Simply Wall St does not hold any of the stocks mentioned.